Honors & Awards
Research Grant, Stanford MedScholars (2015-17)
Ouyang Fellowship, Amherst College (2012)
WAM: Women and Medicine, President (2016-17)
Pacific Free Clinic, Specialty Clinic Manager (2016-17, 2019-20)
Stanford Medical Student Association, Vice President (2016), Class Representative (2017)
A Phase 2 Trial of a Neurokinin-1 Receptor Agonist for the Treatment of Pruritus in Epidermolysis Bullosa (MedScholars Project)
Phase 2 Trial of a Neurokinin-1 Receptor Antagonist for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients: A Randomized Clinical Trial.
Journal of the American Academy of Dermatology
BACKGROUND: Chronic pruritus causes major morbidity in epidermolysis bullosa (EB). The substance P-neurokinin 1 receptor (SP-NK1) pathway is a promising target for treating EB-related pruritus.OBJECTIVE: To evaluate the safety and efficacy of oral NK1 receptor antagonist serlopitant in treating moderate-severe pruritus in EB.METHODS: 14 patients were randomized to serlopitant or placebo for 8 weeks, followed by a 4-week washout and optional open-label extension. The primary endpoint was change in itch as measured by a numeric rating scale (NRS). Secondary endpoints were change in: (1) itch during dressing changes and (2) wound size.RESULTS: We observed greater itch reduction with serlopitant, equivalent to a 0.64-point comparative reduction on the 11-point NRS by week 8, though this failed to meet statistical significance (p=0.11). More serlopitant patients achieved ≥3-point reduction compared to placebo (43% vs. 14%, p=0.35). In post hoc analysis excluding one subject with a concurrent seborrheic dermatitis flare, serlopitant achieved significantly greater median itch reduction from baseline by week 4 (-2 points vs. 0, p=0.01). We observed no statistically significant differences in secondary endpoints. Serlopitant was well-tolerated.LIMITATIONS: Small sample size due to disease rarity CONCLUSION: The potential itch reduction with serlopitant observed in this trial will be pursued by a larger powered trial (NCT03836001).
View details for DOI 10.1016/j.jaad.2019.09.014
View details for PubMedID 31541747
Incidence and Risk of Severe Ileus After Orthopedic Surgery: A Case-Control Study
View details for DOI 10.1007/s11420-019-09712-z
- Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology. Journal of the American Academy of Dermatology 2019
- Dietary carotenoids and bacterial infection in wild and domestic convict cichlids (Amatitlania spp.) ENVIRONMENTAL BIOLOGY OF FISHES 2016; 99 (4): 439–49